Biovica the developer of the DiviTum™ cell proliferation assay

Biovica has developed a simple blood test, DiviTum™, a highly sensitive Thymidine Kinase assay for measuring cell proliferation. One of the most fundamental characteristics of cancer is uncontrolled and increased cell growth. DiviTum™ therefore enables reliable detection, prediction and therapy monitoring of cancer with unprecedented sensitivity and precision.

  • Will the treatment work or not?
  • Is the treatment working or not?

Those are key questions where DiviTum™ have the possibility to make a significant contribution of major value to clinicians and pharma research companies.

 

About DiviTum™

The DiviTum™ technology is easy and efficient:

  • DiviTum measures whats fundamental in cancer; cell proliferation rate.
  • DiviTum requires only a small & simple blood sample (serum) for analysis.
  • DiviTum is the most sensitive and precise test to measure cell proliferation in blood.

Read more about the DiviTum™ cell proliferation assay.

Read more about Thymidine Kinase and its role in cancer.

 

DiviTum™ in your clinical trial

DiviTum™ can accelerate your oncology drug development process and more efficiently evaluate your pipeline compounds. The DiviTum™ technology can increase the productivity of drug innovation and reduce R&D cost.

 

The DiviTum™ technology has demonstrated the ability to:

  • Predict drug efficacy.
  • Stratify patient populations in responders and non-responders.
  • Improve evaluation and monitoring of therapy efficacy during treatment.

Read more about collaboration with Biovica.